April 7, 2011. By Lucy Campbell.
Washington, DC The Food and Drug Administration (FDA) has notified healthcare professionals and patients that it continues to receive reports of methemoglobinemia a serious and potentially fatal adverse effect, associated with benzocaine products both as a spray, used during medical procedures to numb the mucous membranes of the mouth and throat, and benzocaine gels and liquids sold over-the-counter and used to relieve pain from a variety of conditions, such as teething, canker sores, and irritation of the mouth and gums.
Read [
FDA Issues Warning for Benzocaine Topical Products ]
